Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
Drugs in Development
Details:
AIM’s Ampligen (rintatolimod) is being evaluated in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in treating late-stage pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Brand Name: Ampligen
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2024
Lead Product(s) : Rintatolimod,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : Not Applicable
Deal Type : Not Applicable
AIM Reports Positive Data in Study of Ampligen and Imfinzi For Pancreatic Cancer
Details : AIM’s Ampligen (rintatolimod) is being evaluated in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in treating late-stage pancreatic cancer.
Brand Name : Ampligen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2024
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of second-line cholangiocarcinoma.
Lead Product(s): Certepetide,Durvalumab,Cisplatin
Therapeutic Area: Oncology Brand Name: LSTA1
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2024
Lead Product(s) : Certepetide,Durvalumab,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata Treats First Patient in Second-Line Cholangiocarcinoma BOLSTER Trial
Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of second-line cholangiocarcinoma.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 17, 2024
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody, which is currently being evaluated in combination with tremelimumab for unresectable small cell lung cancer.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2024
Lead Product(s) : Durvalumab,Tremelimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMFINZI Plus IMJUDO Shows Unprecedented Survival in Advanced Liver Cancer
Details : Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody, which is currently being evaluated in combination with tremelimumab for unresectable small cell lung cancer.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 16, 2024
Details:
Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with muscle-invasive bladder cancer with cisplatin, gemcitabine.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2024
Lead Product(s) : Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMFINZI Reduces Recurrence Risk by 32% in Muscle-Invasive Bladder Cancer
Details : Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with muscle-invasive bladder cancer with cisplatin, gemcitabine.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2024
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.
Lead Product(s): Certepetide,Durvalumab,Cisplatin
Therapeutic Area: Oncology Brand Name: LSTA1
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Certepetide,Durvalumab,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata’s Certepetide Receives FDA Orphan Drug Designation for Cholangiocarcinoma
Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 05, 2024
Details:
Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of resectable early-stage (IIA-IIIB) non-small cell lung cancer in adults.
Lead Product(s): Durvalumab,Carboplatin,Cisplatin
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2024
Lead Product(s) : Durvalumab,Carboplatin,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMFINZI Approved in the US for Resectable Non-Small Cell Lung Cancer Pre- and Post-Surgery
Details : Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of resectable early-stage (IIA-IIIB) non-small cell lung cancer in adults.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 16, 2024
Details:
Imfinzi (durvalumab, PD-L1 inhibitor) in combination with chemotherapy has been approved in US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer.
Lead Product(s): Durvalumab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2024
Lead Product(s) : Durvalumab,Cisplatin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Imfinzi Approved in US for Resectable Non-Small Cell Lung Cancer
Details : Imfinzi (durvalumab, PD-L1 inhibitor) in combination with chemotherapy has been approved in US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 16, 2024
Details:
Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with limited-stage small cell lung cancer.
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : Durvalumab,Tremelimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMFINZI® (durvalumab) Receives Priority Review for Limited-Stage Small Cell Lung Cancer
Details : Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with limited-stage small cell lung cancer.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.
Lead Product(s): Certepetide,Durvalumab,Cisplatin
Therapeutic Area: Oncology Brand Name: LSTA1
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2024
Lead Product(s) : Certepetide,Durvalumab,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata Therapeutics Completes Enrollment in Phase 2a BOLSTER Trial of Certepetide
Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with durvalumab & chemotherapy for the treatment of cholangiocarcinoma.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 16, 2024
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist peptide drug candidate, which is being evaluated in preclinical models for the treatment of Intrahepatic Cholangiocarcinoma.
Lead Product(s): Certepetide,Durvalumab,Cisplatin
Therapeutic Area: Oncology Brand Name: LSTA1
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2024
Lead Product(s) : Certepetide,Durvalumab,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata Therapeutics’ Certepetide Shows Promise in Cholangiocarcinoma in Preclinical Model
Details : LSTA1 (certepetide) is an integrin alpha-V antagonist peptide drug candidate, which is being evaluated in preclinical models for the treatment of Intrahepatic Cholangiocarcinoma.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 10, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
